Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

被引：0

作者：

Carril-Ajuria, Lucia

Naigeon, Marie

Dalban, Cecile

Desnoyer, Aude

Rioux-Leclercq, Nathalie

Sautes-Fridman, Catherine

Meylan, Maxime

Vano, Yann-Alexandre

Beusenlick, Benoit

Chouaib, Salem

de Oliveira, Caroline

Tantot, Florence

Flippot, Ronan

Escudier, Bernard

Albiges, Laurence

Chaput, Nathalie

机构：

[1] Inst Gustave Roussy, Med Oncol, Villejuif, France

[2] Gustave Roussy, Lab Immunomonitoring Oncol, Villejuif, France

[3] Ctr Leon Berard, Lyon, France

[4] AP HP, Paris, France

[5] Pontchaillou Univ Hosp Ctr, Rennes, France

[6] Sorbonne Univ, Univ Paris Cite, INSERM, Ctr Rech Cordeliers, Paris, France

[7] Univ Paris Cite, Dept Med Oncol, Hop Europeen Georges Pompidou, AP HP Ctr,Inst Canc Paris CARPEM,, Paris, France

[8] Univ Hosp Leuven, Gen Med Oncol, B-3000 Leuven, Belgium

[9] Gustave Roussy Canc Campus, Villejuif, France

[10] Gustave Roussy, Lab Immunooncol, F-94800 Villejuif, France

[11] UNICANCER, Le Kremlin Bicetre, France

[12] Gustave Roussy, Villejuif, MA, France

[13] Univ Paris Sud, Dept Canc Med, Gustave Roussy Canc Campus, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

724

引用

页数：1

共 50 条

[31] Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
Kobayashi, Mizuki
Numakura, Kazuyuki
Hatakeyama, Shingo
Muto, Yumina
Sekine, Yuya
Sasagawa, Hajime
Kashima, Soki
Yamamoto, Ryohei
Koizumi, Atsushi
Nara, Taketoshi
Saito, Mitsuru
Narita, Shintaro
Ohyama, Chikara
Habuchi, Tomonori
GENES, 2022, 13 (07)
[32] Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).
Desai, Kunal
Rybicki, Lisa A.
Nizam, Amanda
Wood, Laura S.
Allman, Kimberly D.
Martin, Allison
Calabrese, Cassandra
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB
Numakura, Kazuyuki
Hatakeyama, Shingo
Sekine, Yuya
Muto, Yumina
Kobayashi, Mizuki
Kashima, Soki
Yamamoto, Ryohei
Koizumi, Atsushi
Nara, Taketoshi
Saito, Mitsuru
Narita, Shintaro
Ohyama, Chikara
Habuchi, Tomonori
JOURNAL OF UROLOGY, 2022, 207 (05): : E175 - E175
[34] Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Martini, Dylan J.
Goyal, Subir
Liu, Yuan
Evans, Sean T.
Olsen, T. Anders
Case, Katherine
Magod, Benjamin L.
Brown, Jacqueline T.
Yantorni, Lauren
Russler, Greta Anne
Caulfield, Sarah
Goldman, Jamie M.
Nazha, Bassel
Harris, Wayne B.
Kissick, Haydn T.
Master, Viraj A.
Kucuk, Omer
Carthon, Bradley C.
Bilen, Mehmet Asim
ONCOLOGIST, 2021, 26 (10): : E1742 - E1750
[35] Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).
McKay, Rana R.
Martini, Dylan
Moreira, Raphael Brandao
Hamieh, Lana
Norton, Craig
Mullane, Stephanie Anne
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[36] Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.
Puchades, C.
Mendez, J. A.
Torres, A.
Rodrigo, C.
Gimeno, G.
Rama, E.
Martinez-Castillo, A.
Caballero Daroqui, J.
Gomez Codina, J.
Juan-Vidal, O.
Lorente, D.
ANNALS OF ONCOLOGY, 2018, 29
[37] Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
Kobayashi, Kazuo
Iikura, Yusuke
Hiraide, Makoto
Yokokawa, Takashi
Aoyama, Takeshi
Shikibu, Sari
Hashimoto, Koki
Suzuki, Kenichi
Sato, Hitoshi
Sugiyama, Erika
Tajima, Masataka
Hama, Toshihiro
IN VIVO, 2020, 34 (05): : 2647 - 2652
[38] Impact of obesity on immune-related adverse events and tyrosine kinase inhibitor side effects in patients with metastatic renal cell carcinoma (mRCC)
Alharbi, Malak
Tariq, Muhammad Junaid
Jatwani, Karan
George, Saby
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
Taigo Kato
Akira Nagahara
Norihiko Kawamura
Wataru Nakata
Tetsuji Soda
Kyosuke Matsuzaki
Koji Hatano
Atsunari Kawashima
Takeshi Ujike
Ryoichi Imamura
Kensaku Nishimura
Shingo Takada
Masao Tsujihata
Seiji Yamaguchi
Tetsuya Takao
Kazuo Nishimura
Norio Nonomura
Motohide Uemura
International Journal of Clinical Oncology, 2021, 26 : 954 - 961
[40] The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
Kato, Taigo
Nagahara, Akira
Kawamura, Norihiko
Nakata, Wataru
Soda, Tetsuji
Matsuzaki, Kyosuke
Hatano, Koji
Kawashima, Atsunari
Ujike, Takeshi
Imamura, Ryoichi
Nishimura, Kensaku
Takada, Shingo
Tsujihata, Masao
Yamaguchi, Seiji
Takao, Tetsuya
Nishimura, Kazuo
Nonomura, Norio
Uemura, Motohide
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 954 - 961

← 1 2 3 4 5 →